Cargando…
Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer
Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration. Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC. Design. Obse...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102728/ https://www.ncbi.nlm.nih.gov/pubmed/27867395 http://dx.doi.org/10.1155/2016/2586512 |
_version_ | 1782466476733628416 |
---|---|
author | Florenzano, Pablo Guarda, Francisco J. Jaimovich, Rodrigo Droppelmann, Nicolás González, Hernán Domínguez, José M. |
author_facet | Florenzano, Pablo Guarda, Francisco J. Jaimovich, Rodrigo Droppelmann, Nicolás González, Hernán Domínguez, José M. |
author_sort | Florenzano, Pablo |
collection | PubMed |
description | Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration. Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC. Design. Observational prospective study. Patients. DTC patients who underwent thyroidectomy, with or without RAI. Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment. Results. 110 patients answered the first survey and 61 both. Nearly 80 percent received RAI. Among early symptoms, periorbital edema, excessive tearing, salivary gland disturbances, dry mouth, taste disorders, and nausea were more frequent and intense among RAI patients. Regarding late symptoms, periorbital edema, salivary gland pain and swelling, and dry mouth were more frequent and intense in RAI patients. Frequency and intensity of adverse effects were not different between low and high RAI doses (50 versus ≥100 mCi). Conclusion. RAI-related symptoms are frequent and usually persist after 6 months of administration, even when low doses are given. This finding must be considered when deciding RAI administration, especially in low risk patients, among whom RAI benefit is controversial. |
format | Online Article Text |
id | pubmed-5102728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-51027282016-11-20 Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer Florenzano, Pablo Guarda, Francisco J. Jaimovich, Rodrigo Droppelmann, Nicolás González, Hernán Domínguez, José M. Int J Endocrinol Research Article Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration. Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC. Design. Observational prospective study. Patients. DTC patients who underwent thyroidectomy, with or without RAI. Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment. Results. 110 patients answered the first survey and 61 both. Nearly 80 percent received RAI. Among early symptoms, periorbital edema, excessive tearing, salivary gland disturbances, dry mouth, taste disorders, and nausea were more frequent and intense among RAI patients. Regarding late symptoms, periorbital edema, salivary gland pain and swelling, and dry mouth were more frequent and intense in RAI patients. Frequency and intensity of adverse effects were not different between low and high RAI doses (50 versus ≥100 mCi). Conclusion. RAI-related symptoms are frequent and usually persist after 6 months of administration, even when low doses are given. This finding must be considered when deciding RAI administration, especially in low risk patients, among whom RAI benefit is controversial. Hindawi Publishing Corporation 2016 2016-10-27 /pmc/articles/PMC5102728/ /pubmed/27867395 http://dx.doi.org/10.1155/2016/2586512 Text en Copyright © 2016 Pablo Florenzano et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Florenzano, Pablo Guarda, Francisco J. Jaimovich, Rodrigo Droppelmann, Nicolás González, Hernán Domínguez, José M. Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer |
title | Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer |
title_full | Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer |
title_fullStr | Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer |
title_full_unstemmed | Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer |
title_short | Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer |
title_sort | radioactive iodine administration is associated with persistent related symptoms in patients with differentiated thyroid cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102728/ https://www.ncbi.nlm.nih.gov/pubmed/27867395 http://dx.doi.org/10.1155/2016/2586512 |
work_keys_str_mv | AT florenzanopablo radioactiveiodineadministrationisassociatedwithpersistentrelatedsymptomsinpatientswithdifferentiatedthyroidcancer AT guardafranciscoj radioactiveiodineadministrationisassociatedwithpersistentrelatedsymptomsinpatientswithdifferentiatedthyroidcancer AT jaimovichrodrigo radioactiveiodineadministrationisassociatedwithpersistentrelatedsymptomsinpatientswithdifferentiatedthyroidcancer AT droppelmannnicolas radioactiveiodineadministrationisassociatedwithpersistentrelatedsymptomsinpatientswithdifferentiatedthyroidcancer AT gonzalezhernan radioactiveiodineadministrationisassociatedwithpersistentrelatedsymptomsinpatientswithdifferentiatedthyroidcancer AT dominguezjosem radioactiveiodineadministrationisassociatedwithpersistentrelatedsymptomsinpatientswithdifferentiatedthyroidcancer |